# BELITE BIO, INC

Summary updated: 2026-10-02T15:29:46.119599Z
Canonical: https://finbar.com/research/companies/belite-bio-inc

## Overview

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for degenerative retinal diseases, particularly Stargardt disease type 1 and geographic atrophy associated with dry age-related macular degeneration. Its lead candidate, tinlarebant, is an oral investigational therapy being studied for these conditions; the company also has a preclinical small-molecule program, LBS-009, for metabolic disorders. [1](https://app.finbar.com/go?id=P150487391)[2](https://app.finbar.com/go?id=P150488036)

The company was incorporated in 2018 and is headquartered in San Diego, California. Its corporate and clinical-development footprint spans the United States and several other markets, including Australia, Hong Kong, mainland China, Taiwan, Switzerland, and Japan. [3](https://app.finbar.com/go?id=P150487364)[4](https://app.finbar.com/go?id=T17237963) Belite Bio describes its mission as “Bringing health insight, treating the untreatable.” [5](https://belitebio.com/about-1/)

Belite Bio remains pre-commercial: its 2025 annual filing reported no revenue to date and a net loss of approximately US$77.6 million for 2025. [2](https://app.finbar.com/go?id=P150488036)[6](https://app.finbar.com/go?id=P150488111)
[1](https://app.finbar.com/go?id=P150487391)[2](https://app.finbar.com/go?id=P150488036)[3](https://app.finbar.com/go?id=P150487364)[4](https://app.finbar.com/go?id=T17237963)[6](https://app.finbar.com/go?id=P150488111)[5](https://belitebio.com/about-1/)

## Products & services

Belite Bio’s lead product candidate is tinlarebant (LBS-008), an investigational, orally administered once-daily tablet being developed for Stargardt disease type 1 (STGD1) and geographic atrophy, an advanced form of dry age-related macular degeneration. It is a potent, reversible small-molecule antagonist of retinol-binding protein 4 (RBP4); by reducing retinol delivery into the visual cycle, it is intended to reduce toxic bisretinoid accumulation and slow retinal damage. It is not an approved commercial product. [7](https://app.finbar.com/go?id=P150487393)[8](https://app.finbar.com/go?id=P150487395)[9](https://app.finbar.com/go?id=P150487490) In August 2026, the FDA accepted the U.S. application for STGD1 for Priority Review; acceptance is not approval. [10](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-us-food-and-drug-administration-acceptance)

LBS-009 is an oral, preclinical-stage small-molecule RBP4 antagonist being studied for metabolic and liver diseases, including non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and type 2 diabetes. It is designed to compete with retinol for RBP4 binding; the resulting complex cannot bind transthyretin and is cleared from circulation by renal filtration. Reported findings are from preclinical studies, not clinical efficacy trials. [11](https://app.finbar.com/go?id=P150487610)[12](https://app.finbar.com/go?id=P150487611)[13](https://app.finbar.com/go?id=P150487612)[14](https://app.finbar.com/go?id=P150487613) Belite reports no approved products for commercial sale and no product-sales or out-licensing revenue; it does not disclose a product-level performance mix or marketed services. [2](https://app.finbar.com/go?id=P150488036)[15](https://app.finbar.com/go?id=P150488889)
[7](https://app.finbar.com/go?id=P150487393)[8](https://app.finbar.com/go?id=P150487395)[9](https://app.finbar.com/go?id=P150487490)[11](https://app.finbar.com/go?id=P150487610)[12](https://app.finbar.com/go?id=P150487611)[13](https://app.finbar.com/go?id=P150487612)[14](https://app.finbar.com/go?id=P150487613)[2](https://app.finbar.com/go?id=P150488036)[15](https://app.finbar.com/go?id=P150488889)[10](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-us-food-and-drug-administration-acceptance)

## Geographic presence

Belite Bio’s principal executive office is in San Diego, California. Its leased office footprint also includes two locations in Taiwan, as well as smaller offices in Shanghai, China, and Sydney, Australia. The company lists subsidiaries with activities including clinical trials in Australia, Hong Kong and China; clinical-trial support, R&D and back-office services in Taiwan; and R&D in the U.S. [3](https://app.finbar.com/go?id=P150487364)[16](https://app.finbar.com/go?id=P150487988)[17](https://app.finbar.com/go?id=P150487989)[18](https://app.finbar.com/go?id=P150487990)[19](https://app.finbar.com/go?id=P150487991)[20](https://app.finbar.com/go?id=P150487992)[4](https://app.finbar.com/go?id=T17237963)[21](https://app.finbar.com/go?id=P150487379)

Clinical-trial activity has spanned Australia, Taiwan, China, Hong Kong, Japan, the U.S. and several European countries, including the U.K., Germany, the Netherlands, France, Belgium and Switzerland. The company reported no approved product for commercial sale and no revenue through its 2025 filing, so it had no realized geographic revenue split to report. It identifies Hong Kong, Taiwan and the U.S. as the main locations of its long-lived assets, without country-level amounts or percentages, and notes exposure to China-related operating and regulatory developments. [22](https://app.finbar.com/go?id=P150488050)[6](https://app.finbar.com/go?id=P150488111)[2](https://app.finbar.com/go?id=P150488036)[23](https://app.finbar.com/go?id=P150489141)[24](https://app.finbar.com/go?id=P150487124)[25](https://app.finbar.com/go?id=P150487143)
[3](https://app.finbar.com/go?id=P150487364)[16](https://app.finbar.com/go?id=P150487988)[17](https://app.finbar.com/go?id=P150487989)[18](https://app.finbar.com/go?id=P150487990)[19](https://app.finbar.com/go?id=P150487991)[20](https://app.finbar.com/go?id=P150487992)[4](https://app.finbar.com/go?id=T17237963)[21](https://app.finbar.com/go?id=P150487379)[22](https://app.finbar.com/go?id=P150488050)[6](https://app.finbar.com/go?id=P150488111)[2](https://app.finbar.com/go?id=P150488036)[23](https://app.finbar.com/go?id=P150489141)[24](https://app.finbar.com/go?id=P150487124)[25](https://app.finbar.com/go?id=P150487143)

## Business segments

Belite Bio reports one operating and reportable segment: research and development of novel therapeutics addressing unmet medical needs. The company’s chief operating decision maker reviews the business on a consolidated basis; no separate product, therapeutic-area, or geographic segments are reported. [15](https://app.finbar.com/go?id=P150488889)

The 2025 Form 20-F discusses tinlarebant and LBS-009 as pipeline programs, with development focused on conditions including Stargardt disease type 1 and geographic atrophy. These programs and indications are not reported as separate business segments. [2](https://app.finbar.com/go?id=P150488036)[26](https://app.finbar.com/go?id=P150486588)[13](https://app.finbar.com/go?id=P150487612)[14](https://app.finbar.com/go?id=P150487613)

No segment revenue or contribution percentages are reported. The company stated it had no approved product and had generated no product-sale or out-licensing revenue; its reported research and development and selling, general and administrative expenses are functional expense categories, not segment contributions. [2](https://app.finbar.com/go?id=P150488036)[27](https://app.finbar.com/go?id=T17237960)
[15](https://app.finbar.com/go?id=P150488889)[2](https://app.finbar.com/go?id=P150488036)[26](https://app.finbar.com/go?id=P150486588)[13](https://app.finbar.com/go?id=P150487612)[14](https://app.finbar.com/go?id=P150487613)[27](https://app.finbar.com/go?id=T17237960)

## Company history

Belite Bio, Inc. was incorporated in the Cayman Islands on March 27, 2018, with Yu-Hsin Lin identified as its founder. The company’s corporate roots trace to Delaware entities established in 2016 under Lin BioScience, and a Columbia University patent license obtained that year was later assigned to Belite. [3](https://app.finbar.com/go?id=P150487364)[28](https://app.finbar.com/go?id=P150488183)[29](https://app.finbar.com/go?id=P150487641)

Belite began clinical development of tinlarebant (LBS-008) for adolescent Stargardt disease in 2020. In April 2022, it completed an initial public offering of American depositary shares and listed on Nasdaq under the ticker BLTE; a partial over-allotment followed in May. [30](https://app.finbar.com/go?id=P150487400)[31](https://app.finbar.com/go?id=P150486020)[32](https://app.finbar.com/go?id=P150483911) Lin became the company’s CEO and chair in November 2021; other leadership milestones included the appointments of CFO Hao-Yuan Chuang in 2020, CSO Nathan L. Mata in 2021, and CMO Hendrik P. N. Scholl in 2024. [33](https://app.finbar.com/go?id=P150488186)[34](https://app.finbar.com/go?id=P150488187)[28](https://app.finbar.com/go?id=P150488183)[35](https://app.finbar.com/go?id=P150488188)

Belite advanced tinlarebant into Phase 3 development for Stargardt disease, with the DRAGON trial completing its last subject visit in September 2025 and top-line results announced in December. Its Phase 2/3 DRAGON II study completed enrollment in 2025. The company also completed Phase 1 studies of tinlarebant for geographic atrophy and had the Phase 3 PHOENIX study underway at year-end 2025. [30](https://app.finbar.com/go?id=P150487400)[36](https://app.finbar.com/go?id=T17237820)[37](https://app.finbar.com/go?id=T17237747) In March 2026, Belite said it was targeting a U.S. FDA NDA submission in the second quarter of that year. [38](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-preliminary-unaudited-fourth-quarter-and-full)
[3](https://app.finbar.com/go?id=P150487364)[28](https://app.finbar.com/go?id=P150488183)[29](https://app.finbar.com/go?id=P150487641)[30](https://app.finbar.com/go?id=P150487400)[31](https://app.finbar.com/go?id=P150486020)[32](https://app.finbar.com/go?id=P150483911)[33](https://app.finbar.com/go?id=P150488186)[34](https://app.finbar.com/go?id=P150488187)[35](https://app.finbar.com/go?id=P150488188)[36](https://app.finbar.com/go?id=T17237820)[37](https://app.finbar.com/go?id=T17237747)[37](https://app.finbar.com/go?id=T17237747)[37](https://app.finbar.com/go?id=T17237747)[38](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-preliminary-unaudited-fourth-quarter-and-full)

## Sources

1. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487391)
2. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488036)
3. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487364)
4. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17237963)
5. [belitebio.com](https://belitebio.com/about-1/)
6. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488111)
7. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487393)
8. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487395)
9. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487490)
10. [investors.belitebio.com](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-us-food-and-drug-administration-acceptance)
11. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487610)
12. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487611)
13. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487612)
14. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487613)
15. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488889)
16. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487988)
17. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487989)
18. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487990)
19. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487991)
20. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487992)
21. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487379)
22. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488050)
23. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150489141)
24. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487124)
25. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487143)
26. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150486588)
27. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17237960)
28. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488183)
29. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487641)
30. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150487400)
31. [BELITE BIO, INC — Full financial report (2022 Y)](https://app.finbar.com/go?id=P150486020)
32. [BELITE BIO, INC — Full financial report (2022 Y)](https://app.finbar.com/go?id=P150483911)
33. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488186)
34. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488187)
35. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150488188)
36. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17237820)
37. [BELITE BIO, INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17237747)
38. [investors.belitebio.com](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-preliminary-unaudited-fourth-quarter-and-full)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.